Derik De Bruin
Stock Analyst at B of A Securities
(4.97)
# 10
Out of 4,829 analysts
210
Total ratings
65.73%
Success rate
88.06%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.04 | +172.28% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $53.50 | +21.50% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $8.35 | +91.73% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $366.52 | +11.86% | 13 | Feb 13, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $156 | $115.05 | +35.59% | 32 | Jan 27, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $98.08 | +40.70% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $430.22 | +53.41% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $155.62 | +51.01% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $144.31 | +45.52% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $218.70 | +62.32% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $23.66 | +9.89% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $249.60 | +8.57% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $175.02 | +3.99% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $40.28 | +98.61% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $199.27 | +45.53% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $24.36 | -38.42% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $5.50 | +281.82% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $9.45 | +164.55% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $23.99 | +33.39% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $80.98 | +23.49% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $58.56 | +46.86% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.18 | +211.38% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,168.56 | +30.50% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.90 | +242.11% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $141.65 | +83.55% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.30 | +1,345.78% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $42.51 | +47.24% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $162.21 | -26.02% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.56 | +252.25% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $508.26 | -53.76% | 3 | Nov 2, 2018 |
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.04
Upside: +172.28%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $53.50
Upside: +21.50%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $8.35
Upside: +91.73%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $366.52
Upside: +11.86%
Agilent Technologies
Jan 27, 2025
Maintains: Neutral
Price Target: $150 → $156
Current: $115.05
Upside: +35.59%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $98.08
Upside: +40.70%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $430.22
Upside: +53.41%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $155.62
Upside: +51.01%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $144.31
Upside: +45.52%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $218.70
Upside: +62.32%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $23.66
Upside: +9.89%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $249.60
Upside: +8.57%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $175.02
Upside: +3.99%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $40.28
Upside: +98.61%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $199.27
Upside: +45.53%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $24.36
Upside: -38.42%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $5.50
Upside: +281.82%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $9.45
Upside: +164.55%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $23.99
Upside: +33.39%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $80.98
Upside: +23.49%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $58.56
Upside: +46.86%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.18
Upside: +211.38%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,168.56
Upside: +30.50%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.90
Upside: +242.11%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $141.65
Upside: +83.55%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.30
Upside: +1,345.78%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $42.51
Upside: +47.24%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $162.21
Upside: -26.02%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.56
Upside: +252.25%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $508.26
Upside: -53.76%